CF
CLYM

Cantor Fitzgerald’s Climb Bio CLYM Stock Holding History

Cantor Fitzgerald’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
+30,000
New +$173K ﹤0.01% 257
2025
Q4 		– Sell
-547,173
Closed -$1.1M – 405
2025
Q3 		$1.1M Sell
547,173
-1,955,358
-78% -$3.63M 0.01% 204
2025
Q2 		$3.1M Buy
2,502,531
+503,116
+25% +$626K 0.06% 80
2025
Q1 		$2.44M Buy
1,999,415
+1,348,915
+207% +$2.19M 0.05% 75
2024
Q4 		$1.17M Buy
+650,500
New +$2.35M 0.02% 83

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cantor Fitzgerald's CLYM Position: Q1 2026 in Review

Cantor Fitzgerald opened a new position in Climb Bio (CLYM) in Q1 2026: 30,000 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #257 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in CLYM as recently as Q3 2025.

Cantor Fitzgerald first reported a position in CLYM in Q4 2024 and has held it in 5 quarters since. The position peaked at $3.1M in Q2 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Cantor Fitzgerald held 30,000 shares of Climb Bio worth $206K as of Q1 2026.
  • Climb Bio was a new Cantor Fitzgerald position in Q1 2026.
  • Climb Bio made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #257 holding.
  • Cantor Fitzgerald first reported a position in Climb Bio in Q4 2024 and has held it in 5 quarters since.
  • Cantor Fitzgerald's Climb Bio position peaked at $3.1M in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.